# GPT 5.2 Review - Reviewer 1/3 (Parallel)

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** medium
**Timestamp:** 2026-01-24T10:36:50.888303
**Review mode:** Parallel (3 independent reviewers)
**Response ID:** resp_0a68bee45448e07f00697492211a308190913f9cf9720a8ce8
**Tokens:** 8208 in / 5056 out
**Response SHA256:** 25c7ce41ea784ca3

---

## Referee Report (top general-interest / AEJ:EP standard)

### Summary
The paper asks an important and policy-relevant question: whether state authorization of dental therapists increases population oral-health access, proxied by adult annual dental visits. Using BRFSS/NOHSS state-level aggregates (even years 2012–2020) and a modern staggered DiD estimator (Callaway–Sant’Anna), the paper reports a **negative** ATT of about **−1.3pp** (Table 3), with a simple pre-trends check that does not reject. The headline result is surprising and potentially publishable, but the current draft falls well short of top-journal standards due to **(i) a too-short and low-frequency panel that makes identification and pre-trend diagnostics weak, (ii) severe concerns about treatment timing/implementation and COVID-era contamination, (iii) limited exploration of mechanisms/heterogeneity, (iv) insufficient engagement with the policy and empirical literature, and (v) presentation that reads like a working paper rather than an AER/QJE/JPE-style contribution.** I view the design as *potentially salvageable* if the authors rebuild the dataset (annual microdata, longer horizon, better treatment timing, stronger inference) and reposition the contribution.

---

# 1. FORMAT CHECK

### Length
- **Fails top-journal norm**. The excerpt shows pages numbered roughly **1–18** including appendix material/figures (e.g., Figure pages 11–12; appendix around 17). That is **< 25 pages** excluding references/appendix. AER/QJE/JPE/ReStud submissions are typically 35–60 pages (main + appendix).
- Action: expand analysis (data, robustness, heterogeneity, mechanisms, alternative designs), not just prose padding.

### References
- The bibliography is **thin** for both (i) DiD/event-study inference and (ii) dental workforce / access policy evaluation. It cites Callaway–Sant’Anna and Goodman-Bacon, plus a small set of domain reports.
- Missing: Sun–Abraham, de Chaisemartin–D’Haultfoeuille, Roth pre-trends sensitivity, Rambachan–Roth, Borusyak et al., Wild bootstrap guidance, plus core health policy evaluation literature on mid-level providers (NPs/PAs) and dental therapist evidence beyond Minnesota reports.

### Prose (bullets vs paragraphs)
- Introduction/background/results/discussion are mostly paragraph-form, which is good.
- However, Section 2.2 uses a bullet list for scope of practice—fine—but the paper at times reads like a policy brief. For a top journal, the intro and discussion need a more cohesive narrative arc and deeper engagement with alternative explanations.

### Section depth (3+ substantive paragraphs each)
- **Introduction**: has several paragraphs—OK.
- **Background**: adequate, but somewhat superficial; needs more on institutional details of authorization vs licensure vs practice, supervision rules, Medicaid billing, and training pipeline.
- **Data/Empirics/Results**: present but not deep enough for publication-quality identification.
- **Discussion**: has multiple paragraphs, but is largely speculative; needs evidence-backed mechanism checks.

### Figures
- Figures 1–2 have axes and visible data; Figure 3 (state panels) appears **small/possibly illegible** in the provided rendering. For a top journal, all figures must be readable in print.
- Event study figure should include clear labeling of which cohorts contribute at each horizon, and the number of states contributing to each event-time.

### Tables
- Tables contain real numbers (no placeholders). Good.
- But the paper lacks the kind of “main regression table” expected: baseline means, alternative specifications, and robustness variants with consistent reporting.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### (a) Standard errors
- **Pass (barely)**: Table 3 reports ATT with **SE** and p-values; text reports SE for the main estimate (Abstract, Section 5.3).
- **Concern**: The event-study coefficients are only shown in a figure; you do **not** report a table of coefficients with SEs and sample sizes by event time. Top journals typically require numeric reporting.

### (b) Significance testing
- **Pass**: p-values shown (Table 3; pre-trends test p = 0.12; main p = 0.041).

### (c) Confidence intervals
- **Pass**: Table 3 includes 95% CI.

### (d) Sample sizes
- You report **N = 245 state-years**, and treated vs control counts (Section 3.3, Table 2; Table 3 notes). **However**, you do not report *effective sample sizes* for each cohort-time ATT(g,t) or event time (how many treated states contribute to each coefficient), which matters greatly with only 9 treated states.

### (e) DiD with staggered adoption
- **Pass conceptually**: Using Callaway–Sant’Anna and avoiding already-treated as controls is the right direction (Section 4.2).
- **But**: key implementation details are missing for reproducibility and inference credibility:
  - Which CS estimator variant (outcome regression / IPW / doubly robust)?
  - What covariates (if any)? It appears none are used (state-level aggregate outcome). That choice needs justification and robustness.
  - How are states weighted (population weights? BRFSS sampling weights? equal-weight state-years?)—critical because your outcome is a proportion derived from complex survey sampling.

### Inference adequacy (major concern even if “passes” checklist)
Even though SEs/p-values exist, inference is not yet credible at a top journal:
- **Only 49 clusters** (states) and only **9 treated**: asymptotic cluster-robust SEs can be unreliable. You should use **wild cluster bootstrap** or randomization/permutation inference (especially given staggered adoption and few treated units).
- Outcome is a **generated regressor** (state-level BRFSS/NOHSS proportion) with its own sampling error. Treating it as observed without accounting for first-stage sampling variance can misstate uncertainty. Using BRFSS microdata with survey weights and design-based SEs would be substantially more credible.

**Bottom line on methodology:** Not “unpublishable” on the narrow checklist, but **not yet publishable** at AER/QJE/JPE/ReStud/Ecta/AEJ:EP because inference and measurement are underdeveloped for the question and the available data.

---

# 3. IDENTIFICATION STRATEGY

### Credibility
The identification claim (“authorization causes changes in population dental visits”) is currently weak because:

1. **Treatment is mismeasured**: “Authorization year” is not “implementation.” Dental therapists enter practice with multi-year lags (training pipeline, rulemaking, Medicaid billing, employer uptake). Your own discussion acknowledges this, but the empirical design does not address it (Sections 4.4, 6.1–6.2).

2. **Panel is too short and low frequency**:
   - Only **five time periods (2012, 2014, 2016, 2018, 2020)** (Section 3.1).
   - Pre-trends are assessed with essentially **one lead** (“t = −4 is the only pre-treatment coefficient used in the parallel trends test,” Figure 2 notes). This is far below top-journal expectations. A non-rejection with one degree of freedom is not persuasive.

3. **COVID-19 confounding (2020)**:
   - Your post period includes 2020, when dental utilization fell sharply and heterogeneously across states due to shutdowns and fear. Several adoptions map into 2020 cohorts (ID, NV, OR, WA; Table 1). Without explicit handling, 2020 can drive spurious “treatment effects.”
   - At minimum: show results excluding 2020, or controlling for COVID intensity/policy restrictions, or using 2021–2023 data to separate post-policy from pandemic shock.

4. **Policy endogeneity is likely first-order**:
   - You mention reverse causality (Sections 6.1, 7), but the design does not address it.
   - In top journals, merely noting endogeneity is not enough; you need an empirical strategy that is robust to it (e.g., synthetic control per adopting state, adoption-instrument design, or explicit pre-trend sensitivity).

### Placebos and robustness
- Robustness is minimal (Appendix B only changes the comparison group; Table 3 second row). That is far from sufficient.

### Do conclusions follow?
- The paper appropriately tempers the causal interpretation somewhat (“may reflect reverse causation”), but the abstract and conclusion still emphasize “authorization is associated with a decrease” and frames it as an effect. Given the identification weaknesses, the causal language should be substantially softened unless the design is strengthened.

### Limitations
- Limitations are acknowledged (Section 6.2), which is good, but these limitations are so central that they currently undermine the publishability of the main claim.

---

# 4. LITERATURE (MISSING REFERENCES + BibTeX)

### What’s currently good
- Correctly cites **Callaway & Sant’Anna (2021)** and **Goodman-Bacon (2021)**.
- Some domain background citations exist (NASEM, CDC, NASHP).

### What’s missing (methods)
You need to engage the modern staggered DiD/event-study literature much more seriously, including estimators, weighting, and pre-trend robustness:

1) **Sun & Abraham (2021)** (event studies with heterogeneous effects; common reference point)
```bibtex
@article{SunAbraham2021,
  author  = {Sun, Liyang and Abraham, Sarah},
  title   = {Estimating Dynamic Treatment Effects in Event Studies with Heterogeneous Treatment Effects},
  journal = {Journal of Econometrics},
  year    = {2021},
  volume  = {225},
  number  = {2},
  pages   = {175--199}
}
```

2) **de Chaisemartin & D’Haultfoeuille (2020)** (TWFE pathologies; alternative DiD)
```bibtex
@article{deChaisemartinD2020,
  author  = {de Chaisemartin, Cl{\'e}ment and D'Haultfoeuille, Xavier},
  title   = {Two-Way Fixed Effects Estimators with Heterogeneous Treatment Effects},
  journal = {American Economic Review},
  year    = {2020},
  volume  = {110},
  number  = {9},
  pages   = {2964--2996}
}
```

3) **Borusyak, Jaravel & Spiess (2021)** (imputation approach; robustness benchmark)
```bibtex
@article{BorusyakJaravelSpiess2021,
  author  = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title   = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  journal = {arXiv preprint arXiv:2108.12419},
  year    = {2021}
}
```

4) **Roth (2022)** / pre-trends sensitivity and power (non-rejection ≠ parallel trends)
```bibtex
@article{Roth2022,
  author  = {Roth, Jonathan},
  title   = {Pretest with Caution: Event-Study Estimates after Testing for Parallel Trends},
  journal = {American Economic Review: Insights},
  year    = {2022},
  volume  = {4},
  number  = {3},
  pages   = {305--322}
}
```

5) **Rambachan & Roth (2023)** (robustness to violations of parallel trends)
```bibtex
@article{RambachanRoth2023,
  author  = {Rambachan, Ashesh and Roth, Jonathan},
  title   = {A More Credible Approach to Parallel Trends},
  journal = {Review of Economic Studies},
  year    = {2023},
  volume  = {90},
  number  = {5},
  pages   = {2555--2591}
}
```

### What’s missing (domain/policy)
Top journals will expect you to position against broader evidence on scope-of-practice expansions and midlevel providers, and empirical work on dental access and Medicaid dental benefits. Examples:

6) **Buchmueller, Miller, Vujicic**-type work on dental coverage/utilization (you cite Vujicic in an ADA brief; you need peer-reviewed economics/health services evidence on utilization elasticities, Medicaid adult dental benefit expansions, etc.). If you cannot find economics-journal articles directly on dental therapy, you must at least cite the closest analogs: nurse practitioner scope-of-practice expansions and access/utilization.

(Without browsing I won’t fabricate citations; but you should add: NP/PA scope-of-practice causal studies; Medicaid adult dental benefit causal studies; and empirical papers on dental provider supply and HPSAs.)

### Why relevant
- Your core challenge is **policy endogeneity + heterogeneous treatment timing + weak pretrends**. The missing methods literature provides tools and expectations (event-study robustness, sensitivity, alternative estimators).
- The missing domain literature provides alternative mechanisms and confounders (coverage expansions, reimbursement, provider supply).

---

# 5. WRITING QUALITY (CRITICAL)

### (a) Prose vs bullets
- Mostly acceptable; bullets are limited. No “fail” here.

### (b) Narrative flow
- The paper has a clear question, but the narrative is not yet top-journal caliber. The introduction (Section 1) states the motivation and method, but it does not yet **build a tight puzzle → hypothesis → empirical challenge → design solution** arc.
- The “counterintuitive negative effect” is a strong hook; lean into it, but then you must *earn it* with stronger design and mechanism evidence.

### (c) Sentence quality
- Generally clear, but somewhat report-like. Many paragraphs summarize rather than argue. For top journals, the prose should more explicitly guide the reader through identification threats and why your approach overcomes them (or what partial identification you can credibly claim).

### (d) Accessibility and magnitudes
- Magnitudes: You report −1.3pp but do not translate into relative terms, or contextualize against typical year-to-year changes in dental visit rates, or against plausible policy effect sizes.
- The estimator is named but intuition is light. A non-specialist would benefit from a short explanation of **why TWFE fails** and what CS does differently, with an intuitive example tied to your adoption cohorts.

### (e) Figures/tables quality
- Needs improvement: event-study should show sample support by event time; Figure 3 is too small; tables should be more comprehensive and standardized.

---

# 6. CONSTRUCTIVE SUGGESTIONS (TO REACH TOP-JOURNAL QUALITY)

## A. Rebuild the data to address the core weaknesses
1) **Use annual BRFSS microdata, not biennial NOHSS aggregates**
- The dental visit question exists annually in BRFSS (in many years). Using microdata allows:
  - many more pre-periods (powerful pre-trends diagnostics),
  - individual covariates and compositional adjustments,
  - correct survey weights and design-consistent SEs,
  - subgroup analyses (income, rural, insurance, race/ethnicity—careful with interpretation).

2) **Extend the time horizon**
- You need more post years, especially after 2020, and ideally pre-2009 if feasible.
- Include 2021–2023/2024 to separate dental therapy implementation from COVID shock and to capture maturation.

3) **Improve treatment measurement**
- Replace “authorization year” with a richer treatment timeline:
  - effective date of rules,
  - first graduating cohort,
  - first licensure date,
  - number of licensed dental therapists per capita (dose-response).
- Consider an event defined by **first non-trivial workforce presence**, not legislation.

## B. Strengthen identification / inference
4) **Inference with few treated states**
- Add **wild cluster bootstrap** p-values and/or **randomization inference** (e.g., reassign adoption years under constraints) to show robustness.

5) **Pre-trend diagnostics and sensitivity**
- Show multiple leads; report event-study coefficients in a table.
- Add **Rambachan–Roth**-style sensitivity bounds: “How big would pre-trend violations need to be to overturn the conclusion?”

6) **Address COVID explicitly**
- Show estimates excluding 2020; show separate 2012–2018 panel estimates; then add post-2020 years.
- Or include controls for pandemic policy stringency / dental office closure intensity (even coarse proxies), and demonstrate robustness.

7) **Policy confounders**
- Control for or stratify by major coincident policies:
  - Medicaid adult dental benefit changes,
  - reimbursement rate changes,
  - other workforce/scope-of-practice reforms.
- A triple-diff using groups more likely to be affected (low-income adults, rural residents, Medicaid-covered) would be far more persuasive than an overall adult average.

## C. Make the result interpretable (mechanisms and heterogeneity)
8) **Target populations**
- Dental therapy is intended for underserved groups. You must test heterogeneous effects:
  - rural vs urban,
  - low-income vs high-income,
  - insured vs uninsured / Medicaid vs private,
  - HPSA vs non-HPSA counties (if you move to county-level data).

9) **Alternative outcomes**
- Dental visits are a blunt measure. Consider:
  - unmet dental need due to cost (BRFSS has cost-barrier items in some years),
  - ED visits for dental conditions (HCUP state ED data),
  - preventive services (cleaning) vs problem-driven visits if available.

10) **Workforce composition**
- Link to dentist counts, hygienist counts, dental therapist counts (where available), and test whether authorization changes provider supply or mix.

## D. Reframe contribution honestly
11) **If endogeneity remains, reposition as “policy response indicator” rather than causal**
- A publishable paper can still be valuable if it convincingly shows adoption is *predictive of declining access* (political economy of adoption), but then the framing must shift: the main contribution becomes understanding adoption and why simple before/after comparisons mislead.

---

# 7. OVERALL ASSESSMENT

### Strengths
- Important policy question with clear motivation (Section 1).
- Correct instinct to avoid TWFE bias and use Callaway–Sant’Anna (Section 4.2).
- Transparent discussion of possible reverse causation (Section 6.1) and acknowledgment of limitations (Section 6.2).

### Critical weaknesses (publication-stopping in current form)
1) **Weak identification due to short, biennial panel and minimal pre-trends support** (Sections 3.1, 5.1–5.2; Figure 2 notes).
2) **Treatment mismeasurement (authorization ≠ implementation)** and likely long lags (Sections 4.4, 6.1–6.2).
3) **2020 COVID confounding** likely contaminates the post period for key cohorts (Table 1; 2020 cohort; Section 3.1).
4) **Inference not yet credible for few treated states + generated aggregate outcomes** (Tables 2–3; Section 3.1).
5) **Literature positioning is incomplete** (References).

### Specific improvements (minimum viable for resubmission)
- Annual BRFSS microdata, longer pre/post, explicit COVID handling, wild bootstrap/randomization inference, richer treatment timing (effective implementation), subgroup effects aligned with policy intent, and major-methods citations + sensitivity analysis.

---

DECISION: REJECT AND RESUBMIT